Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
- Interim KTE-C19 Data, Expected in Second Half of 2016, to Support Planned BLA Filing in Late 2016 and Potential Product Launch in 2017 - ...
-
SANTA MONICA, Calif., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous cell therapy (eACT™)...
-
SANTA MONICA, Calif., Feb. 24, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that it will report fourth quarter and full year 2015 financial results on Monday,...
-
SANTA MONICA, Calif., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that David D. Chang, M.D., Ph.D., Executive Vice President, Research and Development,...
-
SANTA MONICA, Calif., Jan. 13, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that its European subsidiary has entered into a research and license agreement with Leiden...
-
SANTA MONICA, Calif., Jan. 07, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (NASDAQ:KITE) today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the NCI...
-
SANTA MONICA, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (NASDAQ:KITE) today announced that Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer, will...
-
SANTA MONICA, Calif., Dec. 21, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (NASDAQ:KITE) today announced that it has appointed Shawn Tomasello to the newly created position of Chief Commercial...
-
SANTA MONICA, Calif., Dec. 11, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced that the underwriters of its previously announced underwritten public offering have exercised...
-
SANTA MONICA, Calif., Dec. 10, 2015 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (Nasdaq:KITE) today announced the pricing of an underwritten public offering of 3,625,000 shares of its common stock at a...